Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced- calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo will be available […] The post FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions appeared first on Web-Release.
Breaking News:
- Savoye appoints Hakim Ramadan to lead Middle East expansion amid accelerating logistics growth
- Dubai Chamber of Commerce organises seminar to strengthen logistics cooperation between Dubai and Oman with representatives of more than 360 companies
- Object 1 marks Abu Dhabi entry with launch of A1LA Residence on Al Reem Island
- 62% of Saudi leaders are failing to use their data effectively, New Cloudera Report Finds
- beIN SPORTS SECURES RIGHTS TO FIA WORLD ENDURANCE CHAMPIONSHIP ACROSS 35 TERRITORIES
- TheBlueWhale.ai announces new course ‘Top 12 AI Tools to Boost Your Productivity’.
- Mashreq Partners with Toothpick to Launch UAE’s First Digital Loan Solution for Healthcare Services
- 42% of CFOs plan to increase AI investment by over 30% within two years—Bain & Company
Thursday, April 16